Jacobio Pharmaceuticals

Company Presentation

Mission

To Provide Compelling Innovation for Life-changing Medicines

Vision

To Become a Global Leader in R&D

Our Strategy

In-house R&D

Focus on in-house R&D supported by allosteric inhibitor tech platform instead of relying on in-licensing

Global FIC

Focus on R&D of global “first-in-class” drugs instead of me-too drugs

Global Market

Explore global partnership with MNCs to capture global market, not only China opportunities

Full Function Pharm

Span areas of R&D, manufacturing and commercialization in China, not only R&D

Jacobio Team

Yinxiang Wang, Ph.D.

- Chairman and CEO
- Former director and CEO of Betta Pharma
- Former director and CEO of Amgen-Betta
- Chairman on the New Drug R&D Committee of China for PhIRDA (2017-2019)
- Vice Chairman on the Anti-tumor Drug Professional Committee of Chinese Pharmaceutical Association
- Over 20 years of experience in the industry

- Core team worked together for 10+ years, co-founded two companies, developed strong rapport and trust
- Led Betta Pharma's R&D, with experience in development and commercialization of Icotinib hydrochloride (Comana)
- Conmana Received the Zhejiang Province Science and Technology First Class Award in 2012 and the WIPO-SIPO Award for Chinese Outstanding Patented Inventionin 2014
- Strong and complementary skillsets, and aligned aspirations to address urgent medical problems and unmet medical needs

ADMINISTRATION

Xiaojie Wang, EMBA
President of Administration

MEDICAL

Andrea Wang-Gillam*, M.D, Ph.D.
CMO and SVP

CMC, RA & QA

Yunyan Hu
M.S.
SVP

Hong Zhuang*
Ph.D.
SVP of CMC

INFORMATION MANAGEMENT

Haijun Wang*, Ph.D.
SVP of Information Management

MED Chem

Wei Long, Ph.D.
VP of Chemistry

PHARMACOLOGY

Yanping Wang, M.S.
VP of Pharmacology

CMC

Hong Cao, M.S.
VP of CMC

CLINICAL DEVELOPMENT

Yuli Ding, M.S.
VP of Clinical Operations

Bin Fan, ph.D.
VP of Clinical Pharmacology

BIOSTATISTICS & DM

Qiao Li*, Ph.D.
VP of Biostatistics and Data Science

Intellectual Property

Jian Kang*, M.D
VP of Patent

Human Resources

Tiffany Yang*,
VP of HR

** Joined in 2020- 2021*

Our History

Financing Events

2015 & 2016
Series A financing of RMB30mm
BioEngine Capital Inc

Sep 2017
Series B financing of ~US$19mm
QIMING VENTURE PARTNERS
Lilly Asia Ventures 礼来亚洲基金

Aug 2018
Series C financing of ~US$58mm
QIMING VENTURE PARTNERS
HILLHOUSE CAPITAL

Feb 2020
Series C+ financing, of US$26mm
QIMING VENTURE PARTNERS
Lilly Asia Ventures 礼来亚洲基金
HILLHOUSE CAPITAL

Dec 2020
Successful HKEx listing
HKEX 香港交易所

Key Corporate and Product Development Milestones

2015

- Founded in Beijing
- Set sight on SHP2

2016

- Ongoing R&D

2017

- Submitted **IND filing** for JAB-3068 (SHP2) to FDA

2018

- Initiated Phase I clinical trial for JAB-3068 (SHP2) in US/China
- Submitted **IND filing** for JAB-3068 (SHP2) to NMPA

2019

- Initiated Phase I/IIa clinical trial of JAB-3068 (SHP2) in China
- Initiated the Phase I clinical trial for JAB-3312 (SHP2) in US

2020

- **Global partnership with AbbVie regarding SHP2**
- FPI of JAB-3312 in China
- JAB-8263 (BETi) IND approval from FDA & NMPA and FPI in US
- JAB-3312 received orphan drug designation for esophageal cancer from FDA
- KRAS G12D lead identified and first patent filing submitted

Note: The financing time shows when the relevant agreement is signed, and only major investors are included

Major Accomplishments

since January to October 2021

Mar 2021

- **JAB-21822 (KRAS G12Ci) IND submitted to NMPA and FDA**
- JAB-3312 (SHP2i) in combination with anti-PD-1 or MEKi (global phase Ib/IIa) first site initiated in the US
- Jacobio was selected as a constituent of the Hang Seng Composite Index

Apr 2021

- **JAB-21822 (KRAS G12Ci) IND approval from FDA**
- JAB-8263 (BETi) first patient enrolled in China
- JAB-3068 (SHP2i) in combination with the anti-PD-1 first patient enrolled in China
- Launched the third R&D center in Shanghai, China

May 2021

- **JAB-21822 (KRAS G12Ci) IND approval from NMPA**
- JAB-3312 (SHP2i) in combination with anti-PD-1 or MEKi (global phase Ib/IIa) IND approval from NMPA

June 2021

- **JAB-3312 (SHP2i) in combination with anti-anti-PD-1 and MEKi first two patients dosed in the US**

Aug 2021

- **JAB-21822 (KRAS G12Ci) first patient dosed in China**

Oct 2021

- JAB-BX102 (CD73) IND approval from FDA

Pipeline-Clinical Stage

Clinical

Asset	Program	Indications	IND	Phase I	Phase IIa	Recent development	Upcoming Milestone (expected)
JAB-3068 SHP2 abbvie	Mono	Solid tumors	US trial				
	Mono	ESCC, HNSCC, NSCLC	China trial				
	Combo w/PD-1 mAb	ESCC, HNSCC, NSCLC	China trial			IND approved and FPI in April 2021	
JAB-3312 SHP2 abbvie	Mono	Solid tumors	US trial				
	Mono	Solid tumors	China trial				
	Mono	BRAF class 3/ NF1 LOF mutant solid tumors	US trial *				Ph IIa FPI (2021 Q4)
	Combo w/PD-1 mAb	NSCLC, HNSCC, ESCC	Global trial +			IND approved and FPI in May 2021	
	Combo w/MEKi	KRAS mut CRC, Pancreatic cancer	Global trial +			IND approved and FPI in May 2021	
	Combo w/KRAS G12Ci	KRAS G12C mut+NSCLC, CRC	Global trial +				Global Ph Ib/IIa FPI (2021 Q4)
JAB-8263 BET (MYC)	Mono	Solid tumors	US trial				
	Mono	Solid tumors	China trial			IND approved and trials initiated in 2021 Q1	
	Mono	MF and AML	China trial			IND approved and FPI in April 2021	
JAB-21822 KRAS G12C (SHP2/RAS)	Mono	NSCLC, CRC	US trial			IND approved in May 2021 FPI in Sep 2021	
	Mono	NSCLC, CRC	China trial			IND approved in May FPI in July 2021	
	Mono	NSCLC	Global trial *				FPI (2022 1H)
	Mono	NSCLC with STK11 co-mutation	Global trial *			China IND approved in Oct 2021	FPI (2022 1H)
	Combo w/PD-1 mAb	NSCLC	China trial +			IND approved in Oct	FPI (2022 1H)
	Combo w/SHP2i	NSCLC, CRC	China trial +				FPI (2022 1H)
	Combo w/Cetuximab	CRC	China trial +			China IND approved in Dec 2021	FPI (2022 1H)
JAB-BX102 CD73 mAb IO	Mono Combo w/PD-1 mAb	Solid tumors	US trial			IND approved in Oct 2021	FPI（2022 1H)
JAB-2485 Aurora A (MYC/RB)	Mono	Advanced solid tumors	US trial			IND approved in Jan 2022	FPI(2022 2H)

Pipeline-Pre-Clinical Stage

	Asset	Target	Indications	Lead optimization	Candidate IND-enabling	Recent development	Upcoming Milestone (expected)
IND-Enabling	JAB-6343	FGFR4 (RTK)	HCC			GLP-tox and GMP API manufacturing completed	IND (2021 2H)
	JAB-24000	Undisclosed (Tumor metabolic pathway)	NSCLC，HNSCC			Candidate nominated, entering into IND-enabling studies in Mar 2021	IND (2022)
	JAB-BX300	Undisclosed (RAS pathway)	PDAC, CRC			Candidate nominated, entering into IND-enabling studies in Mar 2021	IND (2022)
	JAB-26000	Undisclosed (I/O)	SCLC，HNSCC，ESCC			Lead series identified and patent filed in Jan 2021	IND (2022)
Lead Optimization	JAB-22000	KRAS G12D (RAS)	PDAC, CRC, NSCLC			Lead series identified and patent filed in Nov 2020	IND (2022-2023)
	JAB-23000	KRAS G12V (RAS)					IND (2022-2023)
	JAB-30000	P53					

Jacobio is committed to leveraging in-depth understanding of critical cellular pathways implicated in cancer by selecting important but often challenging drug targets, and developing the world's first-in-class products using its unique drug discovery and technology platform

- RAS Pathway：6 programs
- RB Pathway：1 programs
- MYC Pathway：2 programs
- I/O Therapy：5 programs
- Tumor Metabolic pathway：2 programs
- P53 pathway：3 programs

SHP2 Functions in the Downstream of anti-PD-1 and Upstream of KRAS with Tremendous Market

Mechanisms of Action: RAS Pathway



- SHP2 serves as an important regulator in the growth and survival of cancer cells, transducing upstream RTK signals through the activation of RAS/RAF/MEK/ERK signaling pathways (RAS signaling pathway)

SHP2 Mechanism of Action: in the PD-(L)1 Pathway



- SHP2 is a critical mediator involved in the activation of the PD-1 and BTLA immune checkpoint signal pathways. SHP2 can regulate tumorigenesis by affecting the function of CD8+ T-cells and tumor-associated macrophages (TAM)

Example of SHP2 market potential

1.2 million pts (worldwide in 2019)
0.4 million pts (China in 2019)
SHP2 inhibitor monotherapy population

KRASi / EGFRi / MEKi / ERKi combo
SHP2 combo strategies

Example of KRAS market potential

0.6 million pts (US+China in 2019)
KRAS+ incidence in NSCLC, CRC and PC

40%
Proportion of KRAS G12C mutations of all KRAS mutations

Example of market potential and clinical efficacy of SHP2 in the PD-(L)1 pathway

<30%
ORR of PD-(L)1 monotherapy in most cancer types

3.37 million pts (worldwide in 2019)
Number of patients with the 5 largest cancer types who did not respond to PD-(L)1

62.5% DCR (300mg/d dose group)
DCR of JAB-3068 in PD-(L)1-treated patients in a clinical trial [1]

Note:[1] data cut-off date as of July 24, 2020
Acronyms: NSCLC = non-small cell lung cancer; CRC = colorectal cancer; PC = pancreatic cancer; Frost & Sullivan analysis

Our SHP2 Inhibitors are Well-positioned to Address the Significant Unmet Needs as a Potential First-in-class Drug Globally

Key Highlights and Competitive Advantages

1. **JAB-3068 is the second SHP2 inhibitor that received IND approval from the FDA to enter clinical development**
2. **Dose of JAB-3312 is 4-8mg QD**
   Most potent in this class
3. **Strong anti-tumor activity in tumors with RAS pathway mutations to address the drug resistance for KRAS inhibitors**
4. **Significant potential to be a combo partner with PD-1 inhibitors for treating PD-(L)1 non-responsive, intolerant, or refractory patients**
5. **Potential to be a backbone drug in various high profile combination therapies**

Overview of Global Competitive Landscapes[1]

Company Name	Target	Company	Indication	Phase Stage	Initiation Date[2]
TNO-155	SHP2	Novartis	Advanced solid tumors	Phase I (Mono)	May 2017 (US)
			Cancer	Phase Ib (Combo)	Jul 2019 (US)
			Advanced solid tumors	Phase I/II (Combo)	Apr 2020 (US)
			Solid tumors	Phase I (Combo)	**May 2020 (China)**
JAB-3068	SHP2	Jacobio/ AbbVie	Solid tumors	Phase I (Mono)	Apr 2018 (US)
			Solid tumors	Phase I (Mono)	**Nov 2018 (China)**
			NSCLC, ESCC, HNSCC	Phase IIa (Mono)	**Oct 2019 (China)**
RMC-4630	SHP2	Revolution Medicines /Sanofi	Solid tumors	Phase I (Mono)	Sep 2018 (US)
				Phase I/II (Combo)	Jul 2019 (US)
JAB-3312	SHP2	Jacobio/ AbbVie	Solid tumors	Phase I (Mono)	Sep 2019 (US)
			Solid tumors	Phase I (Mono)	**Jul 2020 (China)**
RLY-1971	SHP2	Relay Therapeutics	Solid tumors	Phase I (Mono)	Jan 2020 (US)

[1] *Source: ClinicalTrials.gov, Revolution Medicines prospectus, Frost & Sullivan analysis*
[2] Denotes the first patient enrollment date

JAB-3312 Most Potent SHP2 Inhibitor

Clinical dose



Preclinical comparison

	JAB-3312	RMC-4550 In-house or ref
SHP2 biochemical IC_{50} (nM)	1.5	10.4
Binding kinetics KD (nM)	0.206	13.6
Cellular p-ERK IC_{50} in NCI-H358 (nM)	3.64	28 (ref)
Cellular p-ERK IC_{50} in KYSE-520 (nM)	0.32	9.1 (ref)
Cellular proliferation KYSE-520 IC_{50} (nM)	3.5	127



Abbvie Partnership in Promoting and Advancing Our Global Development

Transformative Collaboration

- Strategic collaboration to develop and commercialize our SHP2 inhibitors on a global basis
- Leverage a partner's global clinical, regulatory, medical, patient advocacy and commercial footprint

Rights of Parties

- AbbVie will obtain an exclusive license for SHP2 assets worldwide (except for PRC, Hong Kong and Macau)
- Jacobio has the exclusive right to develop and commercialize SHP2 assets in PRC, Hong Kong and Macau

Financial Arrangement

- Upfront Payment (Received) — $45mm
- Milestone Payments — up to $810mm - $20mm received
- Royalties — Low-to-mid Double-digit percentages

AbbVie will **reimburse costs of global clinical development** (incl. China) pre registrational trials

SHP2 Inhibitor-Global Development Plan

Given the unique dual-blockade mechanism of SHP2 against RAS pathway and PD-(L)1 pathway, we plan to develop our SHP2 inhibitors both as monotherapy and as a backbone for various combination therapies

Indication	Mono/Combo	Clinical trial stage	Location	(Expected) First patient in date
JAB-3068				
Solid tumors	Mono	I		Apr 2018
NSCLC, ESCC, HNSCC	Mono	IIa		Oct 2019
NSCLC, ESCC, HNSCC	Combo w/PD-1 mAb	I/IIa		Apr 2021
JAB-3312				
Solid tumors	Mono	I		Sep 2019
Solid tumors	Mono	I		Jul 2020
BRAF class 3/NF1 LOF mutant Solid tumors	Mono	IIa		H2 2021
CRC, pancreatic cancer	Combo w/MEKi	Ib / IIa		Q1 2021
NSCLC, ESCC, HNSCC	Combo w/PD-1 mAb	Ib / IIa		Q2 2021
KRAS G12C-mutant, NSCLC	Combo w/KRAS G12Ci	Ib / IIa		H2 2021

CRC = colorectal cancer; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small cell lung cancer; Q1 = first quarter; Q3 = third quarter

[1] We assume the data of Phase IIb registrational trial will be used for NDA submissions of JAB-3068 and JAB-3312 in China and the U.S.

KRAS Portfolio

Mechanism of RAS Pathway



Market Potential



- JAB-21822 is designed to covalently bind to Cys 12 on KRAS G12C and thereby locking the protein in its GDP-bound, inactive state
- **JAB-21822** has **superior PK Properties** in terms of oral bioavailability and systemic exposures in comparison with AMG510 in monkey, which Indicates potential better therapeutic effects
- **JAB-21822** is able to cross BBB and efficacious in lung brain metastasis model

Our RAS Pathway Pipeline



- *Source: 1. KRAS Mutations in Lung Cancer. Clinical Lung Cancer. 2013, 14(3): 205-214. 2. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Gines, Chromosomes & Cancer. 2011, 50: 307-312. 3. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Cancers. 2020, 12(5): 1341. 4. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov. 2020;19(8):533-552. Frost & Sullivan analysis*

JAB-21822 - Favorable Pharmacokinetics and Safety Profile

A Strong Biochemical and Cellular Activity against KRAS G12C Protein

	JAB-21822	AMG510[2]	AMG510[3]	MRTX849[2]	MRTX849[3]
Biochemical activity IC_{50} (nM)	1.60	3.00	N/A	1.62	N/A
H358[1] p-ERK IC_{50} (nM)	6.77	17.00	27 (Ref 1)	41.00	14 (Ref 2)
H358 cell growth inhibition IC_{50} (nM)	17.40	11.60	4 (Ref 1)	14.50	106.9 (Ref 3)

B Significant Anti-tumor Activity in NCI-H1373 (KRASG12C) Lung Cancer Animal Model



C Superior PK Properties Indicate Potential Better Therapeutic Effects (in Monkeys)

JAB-21822 may have better oral bioavailability and systemic exposures

	JAB-21822	AMG 510[2]	MRTX 849[2]
CL(mL/min/kg), 1mg/kg, iv	6.22	54.9	38.5
T1/2	3.8	2.2	3.9
$AUC_{0\text{-}24h}$(h*μM) / Dose(mg/kg), p.o.	3.87	0.135 (29x)	0.063 (61x)
C_{max} (μM) / Dose(mg/kg), p.o.	1.23	0.069 (18x)	0.008 (154x)
Oral BA (% F)	91.2	26.1 (3x)	9.13 (10x)

D Potential Lower Risk to Elicit Clinical QT Interval Prolongation Compared to MRTX849

Compound	Inhibition % at 10μM
JAB-21822	19.21%
MRTX849[2]	93.64%

[1] NCI-H358 is a NSCLC cell line that harbors KRAS G12C mutation;
[2] our internal pre-clinical studies, AMG 510 and MRTX849 molecules were internally synthesized based on published molecular structures;
[3] Data from public source
Source: Ref 1 Nature, Nov 2019, 575(7781):217-223; Ref 2: 2019AACR; Ref 3: Cancer Discovery, Jan 2020; 10(1):54-71

JAB-21822 KRAS G12Ci - Global Development Plan

Accelerate the clinical development programs of JAB-21822 utilizing strong internal capacities and extensive external resources

- Achieved FPI in China within 2 months after received IND approval
- Multiple arms, as monotherapy and in combination therapies, being advanced in parallel to maximum the competitive advantages

Indication	Mono/Combo	IND / Phase I	Location	Recent development	Upcoming Milestone（expected）
NSCLC, CRC	Mono	*US trial*	🇺🇸	IND approved in May 2021 FPI in Sep 2021	
NSCLC, CRC	Mono	*China trial*	🇨🇳	IND approved in May FPI in July 2021	
NSCLC	Mono	*Global trial*	🇺🇸 🇨🇳		FPI (2022 1H)
NSCLC with STK11 co-mutation	Mono	*Global trial*	🇺🇸 🇨🇳	China IND approved in Oct 2021	
NSCLC	Combo w/PD-1 mAb	*China trial*	🇨🇳	IND approved in Oct 2021	
NSCLC, CRC	Combo w/SHP2i	*China trial*	🇨🇳		
CRC	Combo w/Cetuximab	*China trial*	🇨🇳	China IND approved in Dec 2021	

CRC = colorectal cancer; NSCLC = non-small cell lung cancer; 1H=First Half, Q3 = third quarter

Robust Portfolio Covering Additional Targets With FIC Potential

	Competitive landscape*	Our recent development	Upcoming milestone
JAB-22000 *KRAS G12D (RAS)*	Only several published patent applications identified relating to small molecule KRAS G12Di; No IND globally yet	Lead series identified; First patent filing made in Nov 2020 and subsequent patent filings made to cover multiple directions	2022-2023 IND
JAB-23000 *KRAS G12V (RAS)*	Only several published patent applications identified relating to small molecule KRAS G12Vi; No IND globally yet	Several hits against KRAS G12V have been identified	2023-2024 IND
JAB-24000 *Undisclosed (Tumor metabolic)*	Only one program in Phase I globally	Candidate nominated, entering into IND-enabling studies in Mar 2021; First patent filing made in May 2020	2022 IND
JAB-BX300 *Undisclosed (RAS pathway)*	Only one program in Phase I globally	Candidate nominated, entering into IND-enabling studies in Mar 2021; First patent filing made in Sep 2019	2022 IND
JAB-26000 *Undisclosed (I/O)*	Only one program in Phase I globally	Lead series identified; First patent filing made in Jan 2021	2022 IND

Expanding Our Pipeline to Off-the-shelf Cell Therapies



- Expand our innovative portfolio with new modalities
- Develop and seek collaboration and strategic investment opportunities for compelling biological technologies
- Enhance our capability to explore clinical value of combination therapies between our current programs and off-the-shelf cell therapies

iPSC-NK Is Changing the Game in Cell Therapy

Universal, Off-the-Shelf Cell Products Derived from Renewable Master Cell Lines

	Autologous CAR -T	iPSC Derived NK
Safety		
Graft Versus Host Disease Risk(GvHD)	Low	Low
Cytokine Release Syndrome (CRS) or NeurotoxicityRisk	High	Low
Manufacturing		
Off-the-shelf Product	-	++
Cost of Manufacturing	+++++	+
Ease of Gene Editing	++	+++++
Master Cell Bank	-	+++
Homogeneous Product	+	+++
Batch to Batch Variation	Yes	No
Multiple Dosing	No	Yes
Efficacy		
Persistence	+++++	++
CAR-Independent Tumor Cytotoxicity	-	+

Advantages of iPSC-NK

- Off-the-shelf Availability
- Uniform Product
- Patient Accessibility
- Multiplexed Engineering
- Lower GvHD/CRS risk

iPSC Derived-NK -- Hebecell Platform

3D Culture Without Feeder Cells

NK 1.0

Donor Derived

NK 2.0

iPSC Derived 2D Culture Feeder Cells

Fate THERAPEUTICS
CENTURY
Cytovia
editas
astellas

NK 3.0

iPSC Derived 3D Bioreactor Without Feeder Cells

HebeCell

3D Bioreactor

Cost-effective
industrial scalability

Strategic Layout in Cell Therapy



- Collaborate with Hebecell to develop the next-generation iPSC-NK cell therapy
- Key transaction terms:
  - $25M of consideration in total
  - 19.74% of the share capital (fully-diluted)
  - Dr. Wang Yinxiang was appointed as Chairman of Hebecell
- Expected IND timing – 2022-2023

Summary of Financial Performance

KEY FINANCIAL UPDATES

(RMB mm)

R&D costs [1]



Cash and bank balances [2]



Cash Flow [3]



1 *R&D costs = Cost of revenue + Research and development expenses. All R&D costs in relation to AbbVie Collaboration were recorded in "Cost of revenue" account.*

2 *As of June 30, 2021, the Group did not have any interest-bearing bank and other borrowing.*

3 *Our revenue increased from nil for the six months ended June 30, 2020 to **RMB57.7 million** for the six months ended June 30, 2021, which was attributable to the AbbVie Collaboration. The increased revenue has provided additional cash flow support apart from our financing activities.*

The cash inflow from financing activities during the six months ended June 30, 2021 was mainly from the exercise of over-allotments option, while that during the six months ended June 30, 2020 was mainly from the issuance of Series C+ preferred shares.

Our Expansion

Partnering with Global Pharmas for the Worldwide Market while Developing, Manufacturing and Commercializing for the China Market

Jacobio U.S. R&D Center in Massachusetts

Hebecell in Massachusetts

Beijing Headquarter
Beijing Clinical Operation Center
Beijing R&D and Production Facility
Hebecell China R&D and Production Center (under construction)

Shanghai R&D Center

2020 HC: ~177 employees

2021Q4 HC: 262 employees

Current Location	Location in Preparation / Under Construction	Number of employees
Beijing HQ U.S. R&D Center in MA Shanghai R&D Center	• Beijing R&D and Production Facility (22,000m^2)	By the end of 2020: ~177 By the end of 2021Q4: 262

Note: Touch points in the map are for illustration purpose only.

Key Upcoming Milestones and Catalysts

Event	Expected Timing
JAB-3312，JAB-3068 (SHP2 inhibitor)	
• JAB-3312 + KRAS G12Ci Phase Ib/II FPI	• Q1 2022
JAB-21822 (KRAS G12C inhibitor)	
• Mono in NSCLC Phase IIa FPI	• H1 2022
• Mono in NSCLC with specific co-mutation FPI	• H1 2022
• Combo with anti-PD1 in NSCLC FPI	• H1 2022
• Combo with SHP2i in NSCLC and CRC FPI	• H1 2022
• Combo with Cetuximab in CRC FPI	• H1 2022
JAB-2485 (Aurora A inhibitor)	
• FPI	• H1 2022
JAB-6343 (FGFR4 inhibitor)	
• IND	• H1 2022
JAB-24000（Undisclosed）	
• IND	• H2 2022
JAB-BX300（Undisclosed）	
• IND	• H2 2022
JAB-26000（Undisclosed）	
• IND	• H2 2022

Key Upcoming Milestones and Catalysts

2021-2022H1

Event	Expected Timing
JAB-3312，JAB-3068 (SHP2 inhibitor)	
• JAB-3312 Mono basket trial Phase IIa FPI	• H2 2021
• JAB-3312 + KRAS G12Ci Phase Ib/II FPI	• Jan 2022
JAB-21822 (KRAS G12C inhibitor)	
• Mono in NSCLC Phase IIa FPI	• H1 2022
• Mono in NSCLC with specific co-mutation FPI	• H1 2022
• Combo with anti-PD1 in NSCLC FPI	• H1 2022
• Combo with SHP2i in NSCLC and CRC FPI	• H1 2022
• Combo with Cetuximab in CRC FPI	• H1 2022
JAB-2485 (Aurora A inhibitor)	
• IND	• H2 2021
JAB-6343 (FGFR4 inhibitor)	
• IND	• H2 2021

Jacobio Solution-Global Innovation to Capture Worldwide Opportunities

A global potential first-in-class drug development platform to address challenging targets within critical cancer pathways

Pioneer in designing innovative therapies "drugging the undruggable" empowered by our allosteric inhibitor R&D platform

Partnership with MNC (i.e. AbbVie) in promoting and advancing our global development

SHP2 and KRAS inhibitor assets with tremendous market opportunities

Robust portfolio covering additional targets for other promising pathways

Innovation in new modalities beyond small molecule and biologics

THANKS!